Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GLYR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GLYR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GLYR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GLYR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GLYR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003506511 | Oral cavity | EOLP | regulation of histone acetylation | 14/2218 | 54/18723 | 3.37e-03 | 1.94e-02 | 14 |
GO:00165709 | Skin | AK | histone modification | 84/1910 | 463/18723 | 1.10e-07 | 4.95e-06 | 84 |
GO:00182058 | Skin | AK | peptidyl-lysine modification | 66/1910 | 376/18723 | 7.80e-06 | 1.72e-04 | 66 |
GO:00064736 | Skin | AK | protein acetylation | 39/1910 | 201/18723 | 6.08e-05 | 9.02e-04 | 39 |
GO:00310569 | Skin | AK | regulation of histone modification | 31/1910 | 152/18723 | 1.30e-04 | 1.61e-03 | 31 |
GO:00183946 | Skin | AK | peptidyl-lysine acetylation | 32/1910 | 169/18723 | 4.20e-04 | 4.00e-03 | 32 |
GO:00435436 | Skin | AK | protein acylation | 42/1910 | 243/18723 | 4.59e-04 | 4.28e-03 | 42 |
GO:00183936 | Skin | AK | internal peptidyl-lysine acetylation | 29/1910 | 158/18723 | 1.27e-03 | 9.63e-03 | 29 |
GO:00165736 | Skin | AK | histone acetylation | 28/1910 | 152/18723 | 1.44e-03 | 1.06e-02 | 28 |
GO:00064756 | Skin | AK | internal protein amino acid acetylation | 29/1910 | 160/18723 | 1.55e-03 | 1.12e-02 | 29 |
GO:19019836 | Skin | AK | regulation of protein acetylation | 17/1910 | 77/18723 | 1.66e-03 | 1.18e-02 | 17 |
GO:20007565 | Skin | AK | regulation of peptidyl-lysine acetylation | 13/1910 | 63/18723 | 1.01e-02 | 4.81e-02 | 13 |
GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
GO:003105615 | Skin | cSCC | regulation of histone modification | 68/4864 | 152/18723 | 4.07e-07 | 7.93e-06 | 68 |
GO:000647314 | Skin | cSCC | protein acetylation | 84/4864 | 201/18723 | 6.94e-07 | 1.29e-05 | 84 |
GO:001839414 | Skin | cSCC | peptidyl-lysine acetylation | 72/4864 | 169/18723 | 1.81e-06 | 3.02e-05 | 72 |
GO:00310584 | Skin | cSCC | positive regulation of histone modification | 45/4864 | 92/18723 | 1.92e-06 | 3.17e-05 | 45 |
GO:001820515 | Skin | cSCC | peptidyl-lysine modification | 137/4864 | 376/18723 | 4.09e-06 | 6.09e-05 | 137 |
GO:004354314 | Skin | cSCC | protein acylation | 95/4864 | 243/18723 | 4.56e-06 | 6.71e-05 | 95 |
GO:000647514 | Skin | cSCC | internal protein amino acid acetylation | 66/4864 | 160/18723 | 1.72e-05 | 2.07e-04 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLYR1 | SNV | Missense_Mutation | | c.1559N>T | p.Pro520Leu | p.P520L | Q49A26 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GLYR1 | SNV | Missense_Mutation | | c.622N>A | p.Glu208Lys | p.E208K | Q49A26 | protein_coding | tolerated(0.49) | benign(0.018) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GLYR1 | SNV | Missense_Mutation | novel | c.1483N>C | p.Lys495Gln | p.K495Q | Q49A26 | protein_coding | tolerated(0.42) | benign(0.019) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
GLYR1 | SNV | Missense_Mutation | | c.457N>A | p.Glu153Lys | p.E153K | Q49A26 | protein_coding | tolerated(0.53) | benign(0.012) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLYR1 | SNV | Missense_Mutation | | c.1357G>A | p.Glu453Lys | p.E453K | Q49A26 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLYR1 | insertion | Frame_Shift_Ins | novel | c.328_329insATATTGCCACTTGCCTTCCTGAAAGATTATGCCAGTTTACAGGGAGT | p.Arg110HisfsTer43 | p.R110Hfs*43 | Q49A26 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
GLYR1 | insertion | Frame_Shift_Ins | rs749150409 | c.1140dupG | p.Arg381AlafsTer15 | p.R381Afs*15 | Q49A26 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GLYR1 | SNV | Missense_Mutation | novel | c.452N>G | p.Ser151Cys | p.S151C | Q49A26 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GLYR1 | SNV | Missense_Mutation | | c.1494C>G | p.Phe498Leu | p.F498L | Q49A26 | protein_coding | tolerated(0.34) | benign(0.023) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
GLYR1 | SNV | Missense_Mutation | novel | c.1585N>A | p.Glu529Lys | p.E529K | Q49A26 | protein_coding | deleterious(0) | benign(0.329) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |